openPR Logo
Press release

Cancer Supportive Care Drug Development Market 2019| Abbott Laboratories, AstraZeneca, Astellas Pharma, Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly

01-25-2019 08:24 AM CET | Health & Medicine

Press release from: Cancer Supportive Care Drug Development Market

Cancer Supportive Care Drug Development Market 2019| Abbott

Albany, NY, 25th January : Recent research and the current scenario as well as future market potential of "Cancer Supportive Care Drug Development Pipeline Review, 2017" globally.

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394149

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor.

The size of these pipelines ranges 24 products in cancer anorexia-cachexia syndrome to 52 in cancer pain. The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/cancer-supportive-care-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7

2 Introduction 8
2.1 Cancer Supportive Care Report Coverage 8
2.2 Cancer Anorexia-Cachexia Syndrome Overview 8
2.3 Bone Metastasis Overview 8
2.4 Cancer Pain Overview 8

3 Therapeutics Development 9
3.1 Cancer Anorexia-Cachexia Syndrome 9
3.2 Bone Metastasis 15
3.3 Cancer Pain 21

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1394149

4 Therapeutics Assessment 27
4.1 Cancer Anorexia-Cachexia Syndrome 27
4.2 Bone Metastasis 34
4.3 Cancer Pain 41

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket Ghumare,
ResearchMoz,
90 State Street, Albany NY, United States,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Supportive Care Drug Development Market 2019| Abbott Laboratories, AstraZeneca, Astellas Pharma, Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly here

News-ID: 1532577 • Views:

More Releases from Cancer Supportive Care Drug Development Market

Cancer Supportive Care Drug Development Booming with the Major Players Like Abreos Biosciences Inc, Novartis AG, BiologicsMD Inc, R Pharm and IntelGenx Corp
Cancer Supportive Care Drug Development Booming with the Major Players Like Abre …
Researchmoz added Most up-to-date research on "Cancer Supportive Care Drug Development Booming with the Major Players Like Abreos Biosciences Inc, Novartis AG, BiologicsMD Inc, R Pharm and IntelGenx Corp" to its huge collection of research reports. This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis

More Releases for Anorexia

Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034
Cancer anorexia, often linked with cancer cachexia, is a debilitating condition characterized by loss of appetite, reduced food intake, and progressive weight loss in cancer patients. It is one of the most common and distressing cancer-related complications, affecting up to 80% of patients with advanced cancer. Beyond worsening quality of life, cancer anorexia contributes to poor treatment tolerance, faster disease progression, and higher mortality rates. Download Full PDF Sample Copy of
Cancer Anorexia Market to Reach USD 3.78 Billion by 2034
Cancer anorexia, also known as cancer-related anorexia or anorexia-cachexia syndrome (ACS), is a complex metabolic condition characterized by the loss of appetite and unintended weight loss in cancer patients. It affects up to 50-80% of advanced cancer cases, significantly impacting quality of life, treatment tolerance, and overall survival. While cancer anorexia is not a direct cause of cancer mortality, its complications contribute to increased morbidity and reduced treatment adherence. Download Full
Fighting Cancer Anorexia-Cachexia Syndrome: Global Market Insights 2024-2031
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: Cancer Anorexia-Cachexia Syndrome (CACS) is a debilitating condition characterized by the loss of appetite, muscle wasting, and weight loss in cancer patients. Addressing this syndrome presents a significant challenge in oncology care. In the wake of the COVID-19 pandemic, understanding the dynamics of the global market for CACS drugs becomes paramount. This blog delves into the market size, share, and the impact of COVID-19, while exploring key factors shaping its
Anorexia Memoirist is Dropping Jaws with Mind-Bending Debut Novel
Former Psychiatric Patient Takes Mental Illness For a Twisted and Utterly Gripping Spin In Her Amazon #1 New Release, Glass Half Broken Having played both patient and practitioner, author Rachel Richards' unique experience of psychiatric disorders compelled her to write Glass Half Broken, a newly-released page-turner perfect for psychological suspense novel enthusiasts. Now available on Amazon.com, Glass Half Broken is a fast-paced domestic thriller packed with mystery and a shocking twist! When
Anorexia Nervosa Treatment Market Business Strategies, Developments and Opportun …
Global Anorexia Nervosa Treatment Market Research Report 2018 peaks the detailed analysis of industry share, growth factors, development trends, size, majors manufacturers and 2025 forecast. The report also analyzes innovative business strategies; value added factors and business opportunities. The Anorexia Nervosa Treatment report introduces market competition situation among the vendors and company profile, revenue, product & services, latest developments and business strategies. Global Anorexia Nervosa Treatment market size will reach xx
Research Focused On the Global Anorexia Nervosa Market 2017
MarketResearchReports.Biz presents this most up-to-date research on "Anorexia Nervosa-Pipeline Insights, 2017" Anorexia Nervosa-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anorexia Nervosa. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions,